NRX Pharmaceuticals

NRXP · NASDAQ

$2.62−$0.01 (−0.38%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $2.63

About NRXP

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Employees: 29
Headquarters: Wilmington, Delaware
Listed: Nov 20, 2017
Sector: Health Care
Industry: Pharmaceuticals
Website: nrxpharma.com

Leadership

NRX Pharmaceuticals executives
Name	Title	Since	Age
Jonathan Javitt	—	2021	68
Michael Abrams	—	—	55
Joseph Casper	—	—	75
Riccardo Panicucci	—	—	65
Matthew Duffy	—	—	63
Patrick Flynn	—	—	76
Chaim Hurvitz	—	—	65
Dennis Mcbride	—	—	71
Michael Taylor	—	—	50

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

NRX Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
RELIEF THERAPEUTICS Holding RLF.SW	Supplier and customer	CH	0.88
IQVIA Holdings IQV	Supplier and customer	US	0.43

Similar companies

Companies in the same industry as NRX Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.